ArticleJournal of translational medicine2026
IFITM1-targeted NIR-II fluorescence imaging enables visualisation of colorectal cancer and metastatic lymph nodes.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Interferon-induced transmembrane (IFITM) proteins at the tumour-immune interface: A four-axis framework for their context-dependent roles.Clinical and translational medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundTo improve the visualisation of colorectal cancer (CRC) and its metastatic lymph nodes (LNs), we developed a second near-infrared window (NIR-II; 1000–1700 nm) fluorescent probe using a monoclonal antibody against interferon-induced transmembrane protein 1 (IFITM1). The NIR-II offers advantages for fluorescence-guided resection of CRC and metastatic LNs.
methodsIFITM1 expression in CRC was analysed using The Cancer Genome Atlas (TCGA) database. Clinical tumour specimens were assessed by immunohistochemistry to confirm IFITM1 expression in patients with CRC. An IFITM1–IRDye800CW (IFITM1-800CW) NIR-II fluorescent probe was constructed. It’s in vivo performance was evaluated in subcutaneous CRC xenografts, orthotopic implantation models, and orthotopic LN metastasis models. Surgically resected human CRC specimens were also incubated with the probe to evaluate its clinical utility.
resultsTCGA and tissue analyses showed significantly higher IFITM1 expression in CRC compared with normal tissues (P < 0·001). After intravenous injection of IFITM1-800CW, tumour fluorescence signals appeared at 6 h and peaked within 24 h across all mouse models, enabling robust CRC and LN visualisation. This approach permitted in situ detection of tumours and metastatic LNs as small as 1 mm. In ex vivo human samples, IFITM1-800CW produced significantly higher fluorescence intensity in CRC tissues than in normal or adjacent tissues (P < 0·0001), and allowed identification of tumour margins.
conclusionsIFITM1 is differentially expressed in CRC and represents a promising imaging target. IFITM1-800CW enables sensitive detection of CRC and metastatic LNs, enabling supporting complete tumour resection under NIR-II fluorescence guidance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.